Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug… Sep 14, 2021
Tim Schlidt of Palo Santo Discusses Why Psychedelics Therapy is the Future of End-of-Life Care Sep 13, 2021
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare… Sep 13, 2021
Penn National Drops -4.91% As Sports Betting Stocks Underperform Friday’s Market: Investors Betting On NFL Kickoff… Sep 13, 2021
